An open-label, randomized, Phase III Study of Nivolumab in Combination with Ipilimumab or with Standard Chemotherapy versus Standard Chemotherapy in Patients with previously untreated inoperable or metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO First-line Therapy for untreated, non-resectable or metastatic Urothelial Carcinoma

被引：0
|
作者：
Rexer, H. [1 ]
Retz, M. [2 ]
Waller, C. [3 ]
机构：
[1] AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany
[2] Deutsch Krebsgesell eV, Arbeitsgemeinschaft Urol Onkol, Kuno Fischer Str 8, D-14057 Berlin, Germany
[3] Uniklinikum Freiburg, Innere Med Klin 1, Hugstetter Str 55, D-79106 Freiburg, Germany
来源：
UROLOGE | 2018年 / 57卷 / 07期
关键词：
D O I：
10.1007/s00120-018-0698-z
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：880 / 881
页数：2
相关论文
共 50 条
  • [21] A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41/16 der AUO
    Rexer, H.
    Bergmann, L.
    Steiner, T.
    AKTUELLE UROLOGIE, 2020, 51 (03) : 236 - 238
  • [22] A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
    Galsky, Matt D.
    Necchi, Andrea
    Sridhar, Srikala S.
    Ogawa, Osamu
    Angra, Natasha
    Hois, Stephan
    He, Philip
    Ghiorghiu, Dana C.
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] A phase Ill, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
    Galsky, Matt D.
    Necchi, Andrea
    Sridhar, Srikala S.
    Ogawa, Osamu
    Ruscica, Dario
    Angra, Natasha
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [24] A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
    Choueiri, Toni K.
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Aren, Osvaldo Rudy
    Shah, Amishi
    Kessler, Elizabeth Riley
    Hsieh, James J.
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
    van der Heijden, M. S.
    Gupta, S.
    Galsky, M. D.
    Derleth, C.
    Steinberg, J.
    Kataria, R.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S605 - S606
  • [26] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Powles, T. B.
    Valderrama, B. Perez
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Gauna, D. E. Castellano
    Fornarini, G.
    Li, J-R.
    Gumus, M.
    Mar, N.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    van der Heijden, B. M. S. Homet Moreno
    ANNALS OF ONCOLOGY, 2023, 34 : S1340 - S1340
  • [27] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Powles, T. B.
    Perez Valderrama, B.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano Gauna, D. E.
    Fornarini, G.
    Li, J-R.
    Gumus, M.
    Mar, N.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1557 - S1558
  • [28] First-line Treatment for locally advanced or metastatic Urothelial Carcinoma: A randomized, double-blind Phase-III-Multicenter Study of adjuvant Nivolumab Therapy versus Placebo in Patients with invasive High-Risk Urothelial Carcinoma
    Rexer, H.
    Ohlmann, C. -H.
    Gschwend, J.
    AKTUELLE UROLOGIE, 2018, 49 (04) : 308 - 309
  • [29] Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma.
    Hussain, Syed A.
    Shimizu, Nobuaki
    Obara, Wataru
    Yamasaki, Toshinari
    Takashima, Satoru
    Hasegawa, Takahiro
    Iguchi, Motofumi
    Igarashi, Kenji
    Ogawa, Osamu
    Fujioka, Tomoaki
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [30] Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress).
    Van der Heijden, Michiel Simon
    Gupta, Shilpa
    Galsky, Matt D.
    Derleth, Christina Louise
    Lee, Sue
    Kataria, Ritesh S.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345